Therapeutic Area

Glaucoma

Therapeutic area intelligence for Glaucoma with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 4

Companies

AbbVie →

Alembic Pharmaceuticals →

FDC LTD →

THEA PHARMA →

Assets

Alembic →

FDA →

XEN63 →

Recent signals(4)

StrategyJune 21, 2026

FDA Grants AP Status for Dorzolamide Hydrochloride ANDA205294

The FDA has granted Abbreviated Approval (AP) status for ANDA205294, a generic formulation of Dorzolamide Hydrochloride.

RegulatoryJune 19, 2026

Alembic's ANDA215230 for Brimonidine Tartrate and Timolol Maleate Receives AP Status

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of AP for Alembic's formulation of Brimonidine Tartrate and Timolol Maleate.

ClinicalJune 19, 2026

AbbVie Evaluates XEN63 Gel Stent for Glaucoma via Two Surgical Approaches

A clinical trial is underway to assess the safety and effectiveness of the XEN63 gel stent in glaucoma patients using two different surgical approaches.

RegulatoryJune 6, 2026

FDA Accepts Application for COSOPT PF Supplement by THEA PHARMA

The FDA has accepted the supplemental application NDA202667 for COSOPT PF, a glaucoma treatment.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.